Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors
This study has been completed.
Information provided by:
Memorial Sloan Kettering Cancer Center.
First received: December 20, 2007
Last updated: March 18, 2009
Last verified: March 2009
The purpose of the study is to collect samples of brain or spine tumors. Memorial Sloan-Kettering Cancer Center would then store them for use by researchers who study brain or spine cancer and try to find better ways of treating it. We will also collect blood and spinal fluid from patients with brain or spine tumors. The blood and spinal fluids are also used for research studies of cancer and its treatment.
Primary or Metastatic Central Nervous System (CNS) Tumor
||Observational Model: Case-Only
Time Perspective: Prospective
||Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors
Biospecimen Retention: Samples With DNA
Primary Outcome Measures:
- To establish a repository of CNS tumors or metastases to the CNS and related tissues for current or future studies. [ Time Frame: conclusion of the study ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||March 2009 (Final data collection date for primary outcome measure)
The main objective of the protocol is the establishment of a repository of central nervous system (CNS) tumors or metastases to the CNS and related tissues as an invaluable resource for current or future research studies of the etiology, pathogenesis and treatment of human central nervous system tumors. The database will be established through the intra-operative acquisition of brain or spine tumors as well as the collection of blood and spinal fluids from consenting CNS tumor patients.
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
The patient population will include adult and pediatric patients diagnosed with a primary or metastatic central nervous system tumor.
- For acquisition of intra-operative brain or spine tumor specimens, blood specimens and spinal fluid specimens, all patients who undergo surgery for resection or biopsy qualify for inclusion in this protocol.
- If spinal fluid is not accessed as part of the operative procedure, it will not be collected.
- All patients must be under the care of one or more members of the MSKCC CNS disease management team at the time of tissue acquisition. Patients may have been previously diagnosed and/or treated at another institution.
- Subjects are eligible regardless of sex, age or race.
- Parental or guardian consents will be obtained in the case of minors (less than 18 years of age)
- Patients or their guardians, in case of a minor, may choose to be excluded at any time.
- If a patient, or guardian, decides to withdraw after some or all of the tissues have been collected, such tissues will be destroyed at their request.
- Patients or their guardians will be counseled at the time of obtaining their consent, of the possibility of withdrawing from the protocol.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580463
|Memorial Sloan-Kettering Cancer Center
|New York, New York, United States, 10065 |
Memorial Sloan Kettering Cancer Center.
||Philip Gutin, MD
||Memorial Sloan Kettering Cancer Center.
No publications provided
||Philip Gutin, MD, Memorial Sloan-Kettering Cancer Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 20, 2007
||March 18, 2009
||United States: Institutional Review Board
Keywords provided by Memorial Sloan Kettering Cancer Center.:
ClinicalTrials.gov processed this record on March 26, 2015
central nervous system (CNS) tumor